Journey Medical (DERM) News Today $6.18 -0.03 (-0.48%) Closing price 04:00 PM EasternExtended Trading$6.22 +0.04 (+0.58%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Journey Medical promotes Ramsey Alloush to COOApril 2, 2025 | markets.businessinsider.comJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerApril 1, 2025 | globenewswire.comFY2027 EPS Estimate for Journey Medical Decreased by AnalystJourney Medical Co. (NASDAQ:DERM - Free Report) - Equities researchers at B. Riley decreased their FY2027 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company willMarch 31, 2025 | marketbeat.comRoth Capital Lowers Earnings Estimates for Journey MedicalJourney Medical Co. (NASDAQ:DERM - Free Report) - Analysts at Roth Capital dropped their Q1 2025 EPS estimates for shares of Journey Medical in a report released on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0.19) per share for the quMarch 31, 2025 | marketbeat.comJourney Medical (NASDAQ:DERM) Announces Earnings ResultsJourney Medical (NASDAQ:DERM - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $14.30 million for the quarter, compared to analysts' expectations of $14.21 million.March 29, 2025 | marketbeat.comB.Riley Financial Sticks to Their Buy Rating for Journey Medical Corp (DERM)March 29, 2025 | markets.businessinsider.comRoth Capital Predicts Higher Earnings for Journey MedicalJourney Medical Co. (NASDAQ:DERM - Free Report) - Analysts at Roth Capital upped their Q3 2025 earnings per share (EPS) estimates for shares of Journey Medical in a research note issued on Thursday, March 27th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.1March 29, 2025 | marketbeat.comJourney Medical Corporation (NASDAQ:DERM) Q4 2024 Earnings Call TranscriptMarch 28, 2025 | msn.comJourney Medical reports FY24 EPS (72c) vs (21c) last yearMarch 28, 2025 | markets.businessinsider.comJourney Medical price target lowered to $10.50 from $11 at Alliance Global PartnersMarch 27, 2025 | markets.businessinsider.comJourney Medical Corporation (DERM) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comJourney Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate HighlightsMarch 26, 2025 | globenewswire.comJourney Medical launches Emrosi for the treatment of rosaceaMarch 26, 2025 | finance.yahoo.comJourney Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of RosaceaMarch 24, 2025 | globenewswire.comShort Interest in Journey Medical Co. (NASDAQ:DERM) Expands By 20.5%Journey Medical Co. (NASDAQ:DERM - Get Free Report) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 113,400 shares, a growth of 20.5% from the February 13th total of 94,100 shares. Currently, 1.3% of the company's shares are short sold. Based on an average daily volume of 69,600 shares, the days-to-cover ratio is presently 1.6 days.March 19, 2025 | marketbeat.comJourney Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025March 19, 2025 | globenewswire.comJourney Medical (DERM) to Release Quarterly Earnings on ThursdayJourney Medical (NASDAQ:DERM) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comClaude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) StockJourney Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 49,271 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $5.01, for a total value of $246,847.71. Following the transaction, the chief executive officer now owns 2,003,147 shares in the company, valued at approximately $10,035,766.47. This represents a 2.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 12, 2025 | marketbeat.comJourney Medical Corporation to Participate in the 37th Annual ROTH ConferenceMarch 12, 2025 | globenewswire.comJourney Medical Co. (NASDAQ:DERM) CEO Claude Maraoui Sells 14,905 SharesJourney Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 14,905 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now directly owns 2,052,418 shares of the company's stock, valued at $10,282,614.18. The trade was a 0.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 11, 2025 | marketbeat.comInsider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 14,905 Shares of StockMarch 11, 2025 | insidertrades.comInsider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 18,147 Shares of StockJourney Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 18,147 shares of Journey Medical stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the sale, the chief executive officer now directly owns 2,092,874 shares of the company's stock, valued at $10,736,443.62. This trade represents a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 6, 2025 | marketbeat.comInsider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 23,508 Shares of StockJourney Medical Co. (NASDAQ:DERM - Get Free Report) CEO Claude Maraoui sold 23,508 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $5.19, for a total value of $122,006.52. Following the sale, the chief executive officer now owns 2,139,922 shares in the company, valued at approximately $11,106,195.18. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.March 6, 2025 | marketbeat.comInsider Selling: Journey Medical Co. (NASDAQ:DERM) CEO Sells 18,147 Shares of StockMarch 6, 2025 | insidertrades.comJourney Medical announces results from MVOR-1, MVOR-2 trials publishedMarch 5, 2025 | markets.businessinsider.comJourney Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat RosaceaMarch 5, 2025 | globenewswire.comJourney Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FloridaMarch 4, 2025 | globenewswire.comJourney Medical Corporation (DERM): A Bull Case TheoryFebruary 20, 2025 | msn.comJourney Medical Co. (NASDAQ:DERM) Short Interest UpdateJourney Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 83,800 shares, a growth of 6.5% from the January 15th total of 78,700 shares. Based on an average daily trading volume, of 80,800 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the company's stock are short sold.February 20, 2025 | marketbeat.comRoth MKM Remains a Buy on Journey Medical Corp (DERM)February 7, 2025 | markets.businessinsider.comJourney Medical Corporation's (NASDAQ:DERM) biggest owners are public companies who got richer after stock soared 32% last weekFebruary 5, 2025 | finance.yahoo.comShort Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 14.8%Journey Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 76,800 shares, an increase of 14.8% from the December 31st total of 66,900 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 108,900 shares, the days-to-cover ratio is presently 0.7 days.February 1, 2025 | marketbeat.comJourney Medical Corporation: Emrosi's Launch Could Be A Turning PointJanuary 30, 2025 | seekingalpha.comMinot Light Capital’s Largest Performance Detractor in Q4: Journey Medical (DERM)January 24, 2025 | msn.comJourney Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaJanuary 23, 2025 | globenewswire.comJourney Medical Co. (NASDAQ:DERM) Sees Significant Increase in Short InterestJourney Medical Co. (NASDAQ:DERM - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 76,800 shares, an increase of 14.8% from the December 15th total of 66,900 shares. Based on an average daily trading volume, of 108,900 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the company's shares are sold short.January 19, 2025 | marketbeat.comJourney Medical (NASDAQ:DERM) Shares Down 5.3% - Here's WhyJourney Medical (NASDAQ:DERM) Shares Down 5.3% - Here's What HappenedJanuary 8, 2025 | marketbeat.comJourney Medical Co. (NASDAQ:DERM) Sees Large Increase in Short InterestJourney Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 76,700 shares, an increase of 15.9% from the November 15th total of 66,200 shares. Currently, 0.8% of the company's stock are short sold. Based on an average trading volume of 105,000 shares, the short-interest ratio is presently 0.7 days.December 16, 2024 | marketbeat.comFY2024 EPS Forecast for Journey Medical Lowered by AnalystJourney Medical Co. (NASDAQ:DERM - Free Report) - Research analysts at Roth Capital lowered their FY2024 earnings per share estimates for Journey Medical in a note issued to investors on Monday, November 18th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per shNovember 21, 2024 | marketbeat.comJourney Medical management to meet virtually with B. RileyNovember 21, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Journey Medical Raised by B. RileyJourney Medical Co. (NASDAQ:DERM - Free Report) - Stock analysts at B. Riley upped their FY2024 earnings per share (EPS) estimates for shares of Journey Medical in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst K. Patel now forecasts that the companyNovember 20, 2024 | marketbeat.comDespite Journey Medical's Pullback, Insiders Still Gained US$118kNovember 16, 2024 | finance.yahoo.comJourney Medical Co. (NASDAQ:DERM) Short Interest Down 20.7% in OctoberJourney Medical Co. (NASDAQ:DERM - Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 60,800 shares, a drop of 20.7% from the October 15th total of 76,700 shares. Based on an average trading volume of 88,700 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the company's shares are sold short.November 15, 2024 | marketbeat.comJourney Medical Reports Q3 2024 Earnings, Eyes Emrosi LaunchNovember 15, 2024 | markets.businessinsider.comLake Street Remains a Buy on Journey Medical Corp (DERM)November 13, 2024 | markets.businessinsider.comJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 12, 2024 | globenewswire.comJourney Medical FY2024 EPS Forecast Boosted by Roth CapitalJourney Medical Co. (NASDAQ:DERM - Free Report) - Investment analysts at Roth Capital boosted their FY2024 earnings per share (EPS) estimates for Journey Medical in a report released on Monday, November 4th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per shNovember 7, 2024 | marketbeat.comJourney Medical price target raised to $11 from $8.50 at Alliance Global PartnersNovember 6, 2024 | markets.businessinsider.comQ3 EPS Estimates for Journey Medical Decreased by AnalystJourney Medical Co. (NASDAQ:DERM - Free Report) - Investment analysts at Roth Capital dropped their Q3 2025 EPS estimates for shares of Journey Medical in a report released on Monday, November 4th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.20 per shareNovember 6, 2024 | marketbeat.comFDA Approves New Option for RosaceaNovember 5, 2024 | msn.com Remove Ads Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address DERM Media Mentions By Week DERM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DERM News Sentiment▼0.440.78▲Average Medical News Sentiment DERM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DERM Articles This Week▼22▲DERM Articles Average Week Remove Ads Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Valneva News Today Organogenesis News Today AnaptysBio News Today Pharming Group News Today Prothena News Today Opthea News Today Cogent Biosciences News Today Keros Therapeutics News Today Immatics News Today Arvinas News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DERM) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DERM Stock Free DERM Stock Alerts